



TaeSoo Sean Kim

Partner

sean.kim@icemiller.com

212 824 4962

TaeSoo Sean Kim is a partner in Ice Miller's Business Group and co-chair of the firm's Asia-Pacific Practice Group. Sean represents biotechnology, pharmaceutical, and technology companies in commercial transactions, licensing, mergers and acquisitions, and other strategic business matters.

With a focus in emerging technologies, Sean negotiates complex technology licenses, collaboration agreements, and commercial contracts across fields such as drug discovery, small molecules, cell and gene therapies, artificial intelligence (AI), cryptography, lithium batteries, and other innovative technologies. As a registered patent attorney with a focus on business transactions, he provides strategic guidance on intellectual property (IP) development, IP portfolio management, and IP commercialization to both startups and established companies.

In his role as co-chair of the Asia-Pacific Practice Group, Sean serves as a relationship partner to Asia-based clients in cross-border transactions and disputes, including M&A, joint ventures, commercial agreements, and IP matters. He also leads efforts on large-scale economic development projects, such as lithium battery manufacturing and recycling plants, overseeing site selection, incentives, real estate, and regulatory compliance.

Sean is deeply involved in the startup community, having served on the Board of Korean Startups and Entrepreneurs. He currently serves as outside general counsel to startups, guiding them from pre-funding to multiple rounds of venture financing and exit.

Education

- Stony Brook University (B.S., *departmental honors*, 2008)
 - Chemistry
- Columbia University (M.P.H., 2010)
- Yeshiva University, Benjamin N. Cardozo School of Law (J.D., 2013)

Admissions

- California

Services & Industries

- Asia-Pacific Practice
- Business
- Intellectual Property
- International Legal Services
- Licensing
- Life Sciences & Biotechnology
- Mergers & Acquisitions
- Middle East Practice
- Private Equity
- Software Development & Licensing
- Supply Chain & Logistics
- Technology

- New York
- United States District Court - Eastern District of New York
- United States District Court - Southern District of New York
- United States Patent and Trademark Office

Awards & Honors

- Leadership Council on Legal Diversity, Class of Fellows, 2022

Languages

- Korean

Key Matters

LICENSING TRANSACTIONS

Drafted and negotiated a broad range of collaboration, licensing, co-development and option agreements for pharmaceutical, biotechnology, medical devices, and technology clients, including:

- Represented a Boston-based biotechnology company in out-licensing its mAb therapeutics to a global biopharmaceutical company, with a potential deal value of up to \$800 million plus royalties.
- Represented global clinical-stage biopharmaceutical company in drafting and negotiating a research collaboration agreement with a leading research institution to co-develop novel oncologic drugs, including bispecific antibodies and CAR-T cell products.
- Represented a clinical-stage gene therapy company in licensing and commercial transactions with academic and industry partners on its adeno-associated viral (AAV) vector technologies, including drafting and negotiating sponsored research agreements, material transfer agreements, and license and option agreements.
- Represented a Harvard University spin-off biotechnology company. in negotiating an option and license agreement with a global pharmaceutical company to develop and commercialize tumor necrosis factor (TNF) receptor 2 antagonist antibodies.
- Represented a gene therapy contract manufacturing and therapeutics development company in various license and commercial transactions involving adeno-associated viral (AAV) vector manufacturing process.
- Represented a major Korean Pharmaceutical company on cross-border license agreement, including drafting and negotiating supply agreements and renegotiating an out-licensing deal totaling more than \$2 billion in potential deal value.
- Represented a Korea-based biopharmaceutical company on negotiating a collaboration and license agreement with a San Francisco-based artificial intelligence (AI) drug discovery company.
- Represented a clinical stage biopharmaceutical company in drafting and negotiating a license to drug delivery technologies from a large biopharmaceutical company.
- Represented a Singapore-based clinical stage biotechnology company in drafting and negotiating a development services agreement with a leading biotechnology platform company for monoclonal antibody treatment for COVID-19.
- Represented MIT-spin off biotechnology company in negotiating a collaboration and license agreement with a leading Chinese pharmaceutical company to develop rare disease therapeutics.
- Represented a MEMS sensor and sensing solution company in drafting and negotiating a license and collaboration agreement with a leading national research institution to develop a new sensor technology.
- Negotiated licenses, sponsored research agreements, material transfer agreements, and options with leading academic and research institutions, including MIT, Harvard, Boston University, and Draper Laboratory.

M&A, JOINT VENTURE, AND GENERAL CORPORATE

Drafted and negotiated a broad range of corporate transactions for established and emerging growth companies as well as traditional asset management firms, including:

- Currently representing a publicly-traded Chinese electric vehicle (EV) battery company as a lead counsel in a joint venture with three publicly-traded auto manufacturers to build an electric battery manufacturing plant in the United States on a deal worth \$2 – 3 billion in a total deal value.
- Currently representing a publicly-traded Korean lithium-battery recycling company in all legal matters, including general corporate counseling, real estate purchase of a facility, and environmental permits, as it expands its business expansion in the U.S.
- Currently representing a publicly-traded Korean semiconductor company in expanding its business to U.S., including real estate purchase, corporate structuring and joint venture, and commercial contracts.
- Currently representing a publicly-traded Korean electronic connector manufacturing company in commercial contracts with U.S.-based Fortune 100 companies to supply electronic connector parts from South Korea.
- Currently representing a management team in an ongoing private transaction of a publicly-traded company in a deal worth \$500 – 800 million.
- Represented a gene therapy contract development & manufacturing organization on a \$620 million acquisition to a Japanese multinational food and biotechnology public company.
- Represented a biotech company that develops reagents and filtration processes in a sale to a publicly-traded filtration products and solutions.
- Represented more than twenty (20) Asia-based biotechnology and technology startups and entrepreneurs in corporation formation, venture capital financing, and various corporate transactions.
- Represented a leading Korea-based asset management company in multiple mezzanine loan financing transactions for development projects in New York and Texas.
- Represented a publicly-traded Korea-based semiconductor company in acquiring a commercial property in Silicon Valley to be used for research and development complex in US.
- Represented a publicly-traded German life sciences company and its US subsidiaries in numerous M&A transactions.
- Represented publicly traded SaaS company in its acquisition of a professional networking organization.
- Represented a major U.S. bank in setting up a credit facility for a publicly-traded pharmaceutical company.

Success Stories

Ice Miller Helps Client Secure a Strategic Collaboration with Johnson & Johnson

Ice Miller's South Korea-based client Prazer Therapeutics Inc. (Prazer) has entered into a strategic collaboration and license agreement with Johnson & Johnson (J&J) to advance the discovery of novel therapeutics for neurodegenerative diseases. This partnership follows Prazer's Series B financing led earlier this year by J&J, through its corporate venture capital organization, Johnson & Johnson Innovation (JJDC, Inc.).

Prazer is a biotechnology company developing orally available, brain-penetrant targeted protein degraders with a novel approach to targeted protein degradation (TPD). Their proprietary SPiDEM™ platform is engineered to identify new degradation mechanisms and address limitations associated with traditional bivalent and monovalent protein degraders. This new collaboration with J&J will help Prazer leverage their innovation platform and advance targeted protein degradation to accelerate the discovery of new potential TPD medicines for patients.

The Ice Miller deal team was led by Business group partner TaeSoo Sean Kim and included partner Mai Zymaris and law clerk Kelly Xia (not yet admitted to practice in any jurisdiction). Intellectual Property partners Fabian Koenigbauer and Robert Keeler also provided key assistance. Further assistance was provided by associate Brigid Sharek.

Ice Miller's Life Sciences practice group has extensive experience working with biotechnology companies to help them with seed-stage funding, intellectual property procurement and counseling, and licensing and strategic alliances.

Ice Miller Represents Korean Company in Investing \$107 Million in Opening its United States Manufacturing Facility

Ice Miller represented South Korean-based aluminum manufacturer ALUKO Group in its United States expansion with the opening of a second manufacturing facility in West Tennessee. This project will bring new opportunities to local residents, strengthen the workforce, and support growth across the entire county.

The project is slated to create 285 new jobs in Lauderdale County and bring \$107.7 million in investments to expand the company's integrated aluminum manufacturing operations in Halls, Tennessee. This strategic investment is a significant milestone in ALUKO Group's long-term North American strategy, establishing an eco-friendly supply chain for key American industries like electric vehicles (EVs), solar energy, and construction.

ALUKO Group has been at the forefront of Korea's aluminum extrusion and nonferrous materials industry. Their product portfolio spans industrial applications, including display devices, mobile devices, vehicles, ships, solar module frames, and secondary battery cases, as well as construction materials such as aluminum sheets, curtain walls, and structural frameworks. The ALUKO Group consists of ALUKO, Hyundai Aluminium, Gogang Aluminium, Alutec, KPTU, Hyundai Aluminium Vina, and Alutec Vina.

Ice Miller Business partner TaeSoo Sean Kim led the deal team, with Real Estate, Environmental & Energy Law (REEL) partner Aaron Aft and associate John B. Gregg advising on the real estate transaction and partner Terri Czajka advising on the environmental and permit aspects of the deal.

Ice Miller Assists Two Gene Therapy Companies in Securing Seed Financing

Ice Miller represented two cutting-edge gene therapy companies—Nionyx Bio and Helex—in securing a combined \$7.5 million in seed financing to advance their mission-critical research and development efforts in precision therapeutics for kidney diseases.

Nionyx Bio recently closed a lead-round of approximately \$4 million in seed financing, led by 2048 Ventures and joined by Empire State Development (NY Ventures), White Mug Healthcare, AIN Ventures, and Pathway Bioventures. The funding will support the expansion of Nionyx's proprietary AAV-based delivery platform (Kidney Atlas), the advancement of its gene cassette technologies, and the growth of its team and infrastructure to bring targeted kidney gene therapies closer to clinical development.

Helex secured \$3.5 million in its most recent seed round, led by pi Ventures, with participation from Bluehill Capital, SOSV, and a global syndicate of investors. With this round, Helex has raised over \$6 million in total funding to date. Helex is developing a new class of non-viral, kidney-targeted therapies using its proprietary LNP delivery and AI-based drug-design platforms to address genetic kidney diseases such as autosomal dominant polycystic kidney disease (ADPKD).

Ice Miller Business partners TaeSoo Sean Kim and Dann Bruno represented Helex and Nionyx in the financing, with assistance from associate Zenas Shi. Our Life Sciences practice group has extensive experience working with start-ups to help them with seed-stage funding, intellectual property procurement and counseling, and licensing and strategic alliances.

Ice Miller Counsels MEDiC Life Sciences on Acquisition of Clinical-Stage Oncology Program

Ice Miller represented MEDiC Life Sciences, a biotechnology company pioneering next-generation functional genomics in 3D cancer models, in its acquisition of a clinical-stage oncology program. The asset, which has completed Phase Ib trials in more than 70 patients, marks a significant step in MEDiC's strategy to build a robust therapeutic pipeline.

Through its proprietary SLS™ (Synthetic-Lethal-Gene Signature) biomarker platform, MEDiC identified biomarkers that enhance the program's efficacy by more than 100-fold in preclinical cancer models. With these biomarkers being highly prevalent in cancer patients, the company sees both strong therapeutic potential and a compelling market opportunity.

MEDiC plans to advance the program through investigator-sponsored trials, aiming to validate this biomarker-driven strategy in humans. If successful, the initiative would not only deliver a valuable oncology therapy but also demonstrate the broader power of MEDiC's platform approach.

The Ice Miller team advising MEDiC was led by partner TaeSoo Sean Kim, with support from partners Dann Bruno, Daniel Corsaro, Louis DeLucia, and Weihong Hsing from firm's Business, Bankruptcy & Restructuring, Intellectual Property, and Tax practice groups. Paralegal Michal Shomron also provided valuable support. Ice Miller has served as a trusted advisor to MEDiC across multiple stages of its growth, providing legal and strategic counsel in support of its mission to accelerate the development of next-generation cancer treatments.

Ice Miller Represents Voronoi in Sale of RIPK1 Program to Anvia Therapeutics

Ice Miller represented Voronoi, a South Korean public company, in its asset sales agreement with Anvia Therapeutics, a United States-based biotech company funded by Deerfield, one of the leading venture capital investors in the United States life sciences sector.

The transaction grants Anvia rights to VRN04, Voronoi's oral RIPK1-targeting drug candidate under development for autoimmune, chronic inflammatory, and neurodegenerative diseases. The agreement was executed following Anvia's exercise of an option granted to the company in 2024.

Under the terms of the deal, Voronoi will receive up to \$14.5 million in upfront and milestone payments, payable in both cash and equity, along with royalty on net sales upon commercialization. As part of the upfront consideration, Voronoi received three million shares of Anvia common stock valued at \$3 million. Additional milestone events will trigger further cash payments and share issuances. This transaction highlights the increasing recognition of RIPK1 as a therapeutic target and underscores Voronoi's continued innovation in autoimmune and neuroinflammation therapies.

Ice Miller Business partner TaeSoo Sean Kim led the negotiations, with partners Dann Bruno and Daniel Corsaro assisting on the equity and tax components, respectively.

Ice Miller Represents Korean Client in Financing \$540M Solar Project in Texas

Ice Miller represented the Korea Overseas Infrastructure & Urban Development Corporation (KIND), in connection with financing of the LUCY Solar Project, a 455 MWdc (350 MWac) utility-scale solar facility located in Concho County, Texas, with the "Team Korea" consortium. KIND is an organization established by the government of the Republic of Korea to proactively support Korean companies in investing in global infrastructure development and investment projects through public-private partnership (P3) models.

The project, which broke ground this July, marks a significant milestone for KIND and the broader Team Korea consortium as one of the largest Korean-led renewable energy investments in the United States to date at \$540 million. The Team Korea consortium includes KIND, Hyundai Engineering & Construction Co. Ltd., Korea Midland Power Co., Ltd. (KOMIPO), Hyundai Electric & Energy Systems, Export-Import Bank of Korea (KEXIM), Korea Trade Insurance Corporation (K-SURE), and Korea Development bank (KDB).

The LUCY project is expected to generate approximately 926 GWh annually, supplying clean energy to an equivalent of 260,000 households. The financing secured by KIND and other investors is an excellent example of how public-private collaboration can play a leading role in the global expansion of the domestic renewable energy industry.

Ice Miller Business partner Sean Kim and Real Estate, Environmental & Energy Law (REEL) partner Greg Gorospe represented KIND in securing the financing critical to funding this project.

Ice Miller Helps Colossal Biosciences Secure \$200 Million in Series C Financing to “De-Extinct” the Woolly Mammoth, Thylacine, and Dodo

Ice Miller served as co-counsel in the representation of client Colossal Biosciences, a leading-edge genetic engineering company, in the announcement of its \$200 million Series C financing by TWG Global, a diversified holding company with operating businesses and investments in technology/AI, financial services, private lending and sports and media. Colossal will leverage this latest infusion of capital to continue to advance its genetic engineering technologies while pioneering new revolutionary software, wetware and hardware solutions, which have applications beyond de-extinction including species preservation and human healthcare. Since launching in September 2021, Colossal has raised \$435M in total funding. This latest round of capital places the company at a \$10.2 billion valuation. The Ice Miller team was led by [TaeSoo Sean Kim](#), with support from [Dann Bruno](#), [Josh Borean](#), and Simone Park. Intellectual Property counsel was provided by [Fabian Koenigbauer](#) and [Andrew Baraniak](#).

To learn more about this novel and impactful endeavor, please review Colossal’s [press release](#), which goes into great detail regarding its strides in the scientific breakthroughs toward “de-extinction,” or bringing back extinct species like the woolly mammoth, thylacine and the dodo.

As noted in Colossal’s release, “This funding will grow our team, support new technology development, expand our de-extinction species list, while continuing to allow us to carry forth our mission to make extinction a thing of the past.”

Ice Miller Client Schrödinger Enters into License and Collaboration Agreement with Novartis

Ice Miller client Schrödinger, Inc. (NASDAQ: SDGR) today announced a research collaboration and license agreement with Novartis to advance multiple development candidates into Novartis’s portfolio for further development. The companies also announced an expanded three-year software agreement that substantially increases Novartis’s access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform.

[The full press release can be found here.](#)

As part of the agreement, Schrödinger will receive \$150 million upfront payment, with eligibility to receive up to approximately \$2.3 billion in milestone payments plus royalties on each product commercialized by Novartis.

Ice Miller’s rapidly growing Life Sciences team has been counseling Schrödinger since 2022 and continues to support the company in their growth utilizing its computational predictive modeling technology for drug discovery. The Ice Miller deal team was led by Business Group Partner [TaeSoo Sean Kim](#) and included [Mai Zymaris](#) and Simone Park, with additional deal support from [Nancy Kartos](#) and Xuan Feng. Specialist support was provided by [Anthony Aaron](#) (Regulatory/Antitrust), [Grace Dahm](#) (Regulatory/Antitrust), [Daniel Corsaro](#) (Tax), [Pierce Han](#) (SEC/Capital Markets), [Fabian Koenigbauer](#) (IP), and [Ethan Rii](#) (Healthcare).

Ice Miller Client MEDiC Life Sciences Secures Strategic Investment from LG and Hanmi Pharmaceutical

Known as a leading Silicon Valley-based functional genomics startup, MEDiC Life Sciences has been supported by Ice Miller since 2022. The firm counseled MEDiC in securing a strategic investment by LG and Hanmi Pharmaceutical, two large Korean companies that will accelerate the adoption of MEDiC’s cancer biomarker discovery solution by pharmaceutical partners. The firm has also guided MEDiC in a prior seed funding initiative garnering \$8 million from a group of investors as well as its licensing and collaboration deals.

MEDiC emerged from discoveries made through Stanford University’s SPARK program and has developed a next-generation functional genomics platform to identify novel cancer biomarkers and therapeutic targets for both its internal and external oncology pipelines. MEDiC has partnered with multiple pharmaceutical companies, including Bristol Myers Squibb, to advance its oncology pipelines, while also internally developing its own first-in-class cancer therapies.

Ice Miller works with life science startups, such as MEDiC, at various stages of growth by providing legal and strategic guidance from pre-funding through multiple rounds of venture financing, licensing, and collaboration deals.

This deal is representative of the cross-border transactions that Ice Miller's Asia-Pacific practice has facilitated to aid our clients across the globe in ensuring that they achieve their objectives. Ice Miller partners [TaeSoo Sean Kim](#) and [Josh Borean](#) supported the client, with assistance from associate Simone Park.

Ice Miller Supports Client on “Colossal” Biosciences Advancement

A recent scientific breakthrough by an Ice Miller client has garnered headlines and captured the public's imagination. Colossal Biosciences (Colossal), the world's first de-extinction company, based in Texas, has pushed science a giant step forward through their success in creating a global-first iPSC (induced pluripotent stem cells) from Asian elephant, the closest living cousin of the now extinct woolly mammoth. These iPSC cells can be edited to give mammoth-like traits and allow for the creation of eggs, sperm, and embryos that could then be implanted into an artificial womb to generate an animal. This iPSC advancement could also ultimately help scientists understand Asian elephant's resistance to cancer and could provide deeper insight into the biology of the pachyderm—with a goal of one day creating a species resembling the woolly mammoth.

Founded in 2021, Colossal is primarily focused on conservation efforts and de-extinction, a process of gene engineering technology that rebuilds and reintroduces the DNA of extinct animals once inhabiting the earth. Through this work, Colossal is heavily involved in environmental research and sustainability, driven toward reintroducing and reinvigorating a lost ancestry and climate into our biosphere.

Ice Miller's equally dedicated team has supported Colossal with its patent prosecution and counseling work since 2022, including filing patent applications for technologies leading to the iPSC breakthrough.

Ice Miller Partner [TaeSoo Sean Kim](#) spearheads the Life Sciences Patent Prosecution and IP Licensing team that represents Colossal, with Partner [Fabian Koenigbauer](#) and Senior Patent Agent [Andrew Baraniak](#) serving as co-leads on the efforts. The client team is further supported by [Weihong Hsing](#), [Safet Metjahic](#), [Jacqueline Lesser](#), and [Michael Graham](#).

Ice Miller Represents Forge Biologics in \$620M Acquisition by Ajinomoto

Forge Biologics Holdings, LLC, a Columbus, Ohio-based premier gene therapy contract development & manufacturing organization, has been acquired by the Ajinomoto Group, a Japanese multinational food and biotechnology public company, in an all-cash \$620M deal.

The Ice Miller deal team was led by [Edward Braum](#) and [Dann Bruno](#), with additional corporate support from [Erik Olson](#), [Kevin Burns](#), [Ben Goodman](#), [Chris Michael](#), [Chelsea Abramowitz](#), [Brigid Sharek](#), [Huidi Shu](#), and [Lisa Samblanet](#). [Kathleen Scheidt](#), [Dan Corsaro](#), [Nick Casto](#), [Sean Kim](#), [Holly Banta](#), [Cathy Strauss](#), [Anthony Aaron](#), [Grace Dahm](#), [Nick Reuhs](#), and [Brian Harvey](#) provided specialist support.

Ice Miller has represented Forge since its inception in 2020 through its various rounds of venture capital financing, including its \$40M Series A financing in 2020, \$120M Series B financing in 2021, and \$90M Series C financing in 2022. Ice Miller Business Group partners [Edward Braum](#) and [Sean Kim](#) have represented Forge through its growth, with Ed overseeing the structuring and financing of the company, and Sean facilitating licensing and day-to-day commercial transactions.

This representation further highlights Ice Miller's rapidly growing life sciences practice, with the acquisition placing Forge in a position for long-term growth. The transaction also supports Ajinomoto's desire to extend its development and manufacturing of gene therapies worldwide.

Ice Miller Represents EVE Energy in a \$3B Joint Venture for Battery Cell Production in the U.S.

Ice Miller is representing EVE Energy Co., Ltd. (EVE), a global lithium battery company, in a joint venture with Accelera by Cummins, Daimler Truck and PACCAR to build a manufacturing plant in the United States, which is expected to have a range of \$2 to \$3 billion in total investment. This strategic joint venture will manufacture battery cells for commercial vehicles to help transition into clean energy.

Ice Miller Business Group partners Sean Kim and Edward Braum represent EVE as external counsel, with Sean as lead counsel responsible for overseeing the structuring and negotiation of the transaction. The deal team also includes Simone Park, Huidi Shu, Cody Laska, Josh Borean, Daniel Corsaro, Safet Metjahic, Ming He, Anthony Aaron, Dale Stackhouse, Grace Dahm, John Pence, and Mike Flint.

The location of the manufacturing plant is to be determined.

Thought Leadership

March 11, 2026

The BIOSECURE Act in 2026: Rethinking Exposure in the Life Sciences Industry

February 20, 2026

Navigating Structural Change in Biopharma: A Client Relationship Perspective for United States Industry Leaders

August 25, 2025

Capital Sources for Large-Scale Manufacturing and Infrastructure Projects

2025

BIO KOREA 2025 | Biosecure Act Article

2025 BIO KOREA International Convention Program

June 17, 2024

Increased Tariffs on Chinese Electric Vehicles and Other Goods Expected to Impact Numerous Economic Sectors

February 6, 2023

De-Facto Non-Competes in the FTC's Proposed Rulemaking

Speaking Engagements

- Speaker, "Biotech Legal Forum: Navigating M&A, Licensing, and Partnerships," Korea Health Industry Development Institute (KHIDI), March 2025
- Moderator, "Leveraging Big Data, Artificial Intelligence, and Patents for Business Growth," Korea Society, November 2020
- Speaker, "Intellectual Property Strategies," LA BioStart Legal Basics Program, February 2019
- Speaker, "Digital Health IP considerations," Multi-CLE program in Los Angeles, January 2019
- Moderator, "Raising VC Funding for Life Sciences Startups," Biotech Connection Los Angeles, November 2018
- Speaker, "Legal Considerations for Startups," GRID 110 Incubator, December 2016
- Moderator, "Global Patent Strategies," International Association of Korean Lawyers (IAKL) Conference, October 2016
- Speaker, "Startup Law 101: Incorporation, Fundraising, and IP Strategy for Startups," Korean Startup Summit NYC, June 2016
- Speaker, "U.S. Venture Capital and Legal Considerations for Startups," Samsung Startup Incubator, December 2015
- Speaker, "Technology Commercialization for Korean Universities," U.S. Technology Roadshow, November 2015
- Speaker, "Business Organization and Intellectual Property Strategy for Startups," Korean Startup Showcase NYC, April 2015
- Speaker, "Intellectual Property in M&A and Venture Capital," Global K-Startup Business Program, November 2014
- Panelist, "Corporate and Intellectual Property Law," Harvard Law School, November 2014
- Moderator, "International Career Advice and Experience," International Association of Korean Lawyers (IAKL) Conference, October 2014
- Speaker, "Intellectual Property Strategy for Startups," Korean Startups and Entrepreneurs (KSE), July 2014

- Moderator, "Intellectual Property in Films," WIPO World IP Day, Benjamin N. Cardozo School of Law, April 2014
- Moderator, "The America Invents Act and Its Impact on Patent Litigation and Prosecution," Benjamin N. Cardozo School of Law, April 2014
- Speaker, "Understanding Intellectual Property Rights," CMP Business Outreach Center, November 2013
- Moderator, "Traditional Intellectual Property Protection in the U.S.," 2013 Korea Trade-Investment Promotion Agency (KOTRA) Intellectual Property & Business Strategy Forum, June 2013
- Moderator, "Intellectual Property as a Business Asset and Strategy," Benjamin N. Cardozo School of Law, March 2013
- Moderator, "Korea-US FTA and Its Impact on Intellectual Property," New York City Bar Association, February 2013